Tech Company Financing Transactions
Arrivo BioVentures Funding Round
Arrivo BioVentures closed a $100 million Series B investment round on 11/29/2023. Backers included Orlando Health, Rex Health Ventures and Solas Bioventures.
Transaction Overview
Company Name
Announced On
11/29/2023
Transaction Type
Venture Equity
Amount
$100,000,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds to advance its first-in-class treatment for major depressive disorder (MDD), SP-624, through the completion of a Phase 2b/3 clinical trial and complete a Phase 2 Proof-of-Concept study with its novel treatment to prevent patients with pancreatitis advancing to severe acute pancreatitis, RABI-767.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
3000 RDU Center Drive Suite 130
Morrisville, NC 27560-9731
USA
Morrisville, NC 27560-9731
USA
Phone
Website
Email Address
Overview
Developer of reformulated biopharmaceutical drugs designed to identify biologics and small molecules to improve patient care. The company's drugs are produced by a new chemical entity, to identify regulatory strategies, to expedite the path through efficient clinical programs, enabling biotech companies to meet their drug demands and improve patients' lives.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Stephen Butts
Chief Financial Officer
Karen Adams
Browse more venture capital transactions:
Prev: 11/29/2023: Revela venture capital transaction
Next: 11/29/2023: Modo Energy - It's Diff venture capital transaction
Share this article
Where The Data Comes From
We report on every notable VC transaction. VC transactions reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs